🌍·18h agodiscovery
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Publisher
A
AstraZeneca US
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- AstraZeneca US
- Region
- Global
- Scope
- discovery
- Published
- June 29, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: AstraZeneca US
Scope: discovery
Related coverage
More related coverage
openFDA Drug Labels/-591m ago
Drug label update: Loperamide Hydrochloride
Official structured record identifier: 52e6ecc5-5f3d-9989-e063-6294a90af2dc.
openFDA Drug Labels/-591m ago
Drug label update: NYSTATIN
Official structured record identifier: 50737729-a4a4-e747-e063-6394a90adcc5.
Investing.com Canada/2h ago
Dianthus launches phase 3 trial for myasthenia gravis treatment By Investing.com
Endpoints News/2h ago